Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA-based Chemo-free Bridging/Maintenance in CAR-T for High-risk R/R B-NHL
NCT06646666Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RJ CAR-T 002, tretinoin and zanubrutinib in B-cell non-Hodgkin lymphoma, sponsored by Ruijin Hospital. Primary endpoint: Complete Response Rate at 3 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
RJ CAR-T 002tretinoinzanubrutinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06646666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646666.